Developing new treatments targeting NSD2 for cancer therapy
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY
This study is looking for new medicines that can help fight certain childhood cancers by targeting a protein called NSD2, which is linked to cancer growth, and if successful, these treatments could help kids with these types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10881731 on NIH RePORTER |
What this research studies
This research focuses on discovering new drugs that can degrade the NSD2 protein, which plays a significant role in the development of certain cancers, particularly in children. By targeting NSD2, the research aims to reduce the levels of a specific chemical mark on DNA that is associated with cancer cell growth. The approach involves studying how NSD2 mutations affect cancer progression and testing potential drug candidates in laboratory settings using cancer cell lines. Patients may benefit from these new therapies if they are effective in treating cancers linked to NSD2 dysregulation.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adolescents diagnosed with acute lymphoblastic leukemia or other cancers linked to NSD2 mutations.
Not a fit: Patients with cancers not associated with NSD2 dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for cancers associated with NSD2, improving outcomes for affected patients.
How similar studies have performed: Other research has shown promise in targeting epigenetic regulators like NSD2, indicating potential for success in this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: James, Lindsey Ingerman — Univ of North Carolina Chapel Hill
- Study coordinator: James, Lindsey Ingerman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.